[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-valve-regurgitation-degenerative-or-functional\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-valve-regurgitation-degenerative-or-functional":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100433119","tvmr-with-the-innovalve-system-trial---early-feasibility-study-100433119",false,"NCT04919980","TVMR With the INNOVALVE System Trial - Early Feasibility Study","TWIST-EFS","Inclusion Criteria:\n\n* Clinically significant, symptomatic mitral regurgitation\n* High risk for open-heart surgery\n* Meets anatomical criteria\n\nExclusion Criteria:\n\n* Unsuitable anatomy\n* Patient is inoperable\n* EF\\\u003C25%","ALL","18 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"NA","Study to evaluate the safety and performance of the INNOVALVE system",[26],"Mitral Valve Regurgitation (Degenerative or Functional)","RECRUITING","2026-05-26",{"date":30,"type":31},"2026-05-28","ACTUAL",{"date":33,"type":31},"2022-09-01",{"date":35,"type":20},"2031-07-01",{"name":37,"class":38},"Edwards Lifesciences","INDUSTRY",20,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":5},"100607413","mitral-annular-repair-with-the-cathhelix-transcatheter-system-in-subjects-with-fmr-100607413","NCT07188233","Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With FMR","A Study to Evaluate the Feasibility and Safety of Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With Functional Mitral Regurgitation","MARCH","Inclusion Criteria:\n\n* Moderate to severe (3+) or severe (4+) functional mitral regurgitation\n* Left ventricular ejection fraction ≥30%\n* Symptomatic New York Heart Association (NYHA) Class II to IV).\n\nExclusion Criteria:\n\n* Oxygen dependent for COPD\n* Active or suspected endocarditis\n* Severe symptomatic carotid stenosis\n* Has undergone heart transplantation.\n* Severe calcification of the mitral annulus or leaflets\n* Coronary sinus anatomy that may preclude proper treatment with the device",{"count":49,"type":20},5,[23],"Patients with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) will be evaluated for treatment using the CathHELIX Transcatheter Mitral Annuloplasty System.",[26],"2025-09-20",{"date":55,"type":31},"2025-09-23",{"date":57,"type":31},"2024-11-16",{"date":59,"type":20},"2026-07",{"name":61,"class":38},"HVR Cardio Oy"]